Latest Updates view all

Have you heard of our GEI Program? Looking to hire interns fr STEM backgrounds? Up to $15K... [Read More]
Looking to hire new grads from science/tech/engineering/math? Check out our Graduate Enter... [Read More]
Check it out! RT @venturelondon Have you seen our 2012 winners & finalists yet? Check ... [Read More]
Find The Stiller Centre on Facebook

Tenant news: COTI to Deliver Podium Presentation on COTI-2 at Influential Scientific Conference

Submitted by aggie on Tue, 11/01/2011 - 14:27

London, Ontario (November 1, 2011): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT), a predictive Artificial intelligence technologiy company specializing in accelerating the discovery of small molecules, announced today that Dr. Wayne Danter, COTI's CEO and CSO, will be delivering a podium presentation on Wednesday, November 2, 2011 at 2:55pm Eastern time at Discovery on Target: Emerging Targets for Kinase Inhibitor Pipeline held at the Park Plaza Hotel and Towers in Boston, MA.  The presentation is entitled COTI-2: A highly effective and selective modulator of AKT/AKT2 protein levels and phospho-activation for the treatment of susceptible human cancers.

This presentation will highlight the scientific results from recent pharmacodynamic and pharmacokinetic experiments, which demonstrate COTI-2's ability to significantly inhibit the growth of caner cells that over express AKT/AKT2, confirming it as a targeted therapy candidate.  "This upcoming presentation affords us the opportunity to share our insights into the potential for COTU-2 with a targeted scientific audience of key influencers from many partnering organizations." said Dr. Danter.  "I am delighted to have the opportunity to share with this audience the exciting results of our most recent experiments, highlighting the potential of COTI-2 as a highly selective and well tolerated targeted oncology therapy candidate."

COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express AKT/AKT2.  Over expression of AKT/AKT2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung.  The percent of tumors producing excess active AKT/AKT2 ranges from 20 to 100%, depending on the cancer type.  COTI-2 is the most advanced compound in COTI's pipeline discovered through  CHEMSAS®, a proprietary artificial intelligence platform.

For more details on COTI and this press release, please go their website.